Wednesday, June 23, 2010

Alexander Cherkasky and confirmed inventions of Alexander Cherkasky

My name is Alexander Cherkasky, I am biologist with Masters of
Science degree, now PhD student and am award-winning and
media-highlighted inventor in biology, chemistry and material science,
originator of biomedical problem solutions, which
were successfully confirmed by experiments. I have unique abilities
and expertise, especially in creation, improvement and evaluation of
intellectual property (especially covering solutions of biomedical
problems and new materials) where I offer cooperation. I can determine
the quality of intellectual property and thus the value of companies
especially the basis values of start ups and rollups.
I also offer jointly commercialization of my inventions for which I
have issued patents and published patent applications.
My inventions covered by patents and patent applications, include new
anticancer, antiautoimmune and anti-inflammatory treatments, novel
multiparallel diagnostic systems, novel fast genome sequencing
systems, new lubricants and new materials. I have 35 publications in
patent literature including German patents, US patent applications,
international PCT patent applications and German patent applications.
I got 7 German patents and have also 4 published US patent
I invent since early youth and as I was student at Goethe-Gymnasium in
Dusseldorf, I presented my inventions of Anti-Alzheimer's disease
fusion proteins and anticancer fusion proteins on scientific youth
competitions "Youth researches" (Jugend forscht) in the years 1999 and
2000. It evoked interest of journalists. About me and inventions of
mine reported known newspapers and magazines including the most
popular magazine in Germany Stern (The Star), Bild der Wissenschaft
(Picture of Science), Rheinische Post (The Rhein Post), Westdeutsche
Zeitung Westgerman Newspaper) and other media.
I am also the inventor of ordered DNA winding around the bobbins (my
German Patent DE19929530).
In the year 2003, I was awarded the Bronze Medal "For Outstanding
Achievements" and the Honorary Certificate of the International
Exhibition and Competition of Inventors "Ideas-Inventions-New
Products" IENA 2003 in Nuremberg. IENA is the largest international
inventors exhibition and competition in Germany already over 60
My name was also placed on the Young Inventors International Hall of
Fame. I was only one inventor from Germany whose name was placed on
this Hall of Fame.
Certain inventions of mine were confirmed by others:

1. Micromet (NASDAQ:MITI) does not disclose the fact that Micromet’s key anticancer inventions (US patents US7635472 and US7235641 and US patent applications US20070249529, US20090291072 and US20090022738 are not inventive because of my prior intellectual property (German patents DE 10161738 for Fusion Proteins against T cell tumors, DE10161899 for Fusion Proteins against Hodgkin’s disease and patent applications DE10162870 for Fusion Proteins against B cell tumors and DE 19925052, where also multimeric anticancer fusion proteins are disclosed. These my publications in patent literature damage novelty worldwide). The following points are the same between my prior inventions and these Micromet’s inventions:

1. both are fusion proteins, both are recombinant protein constructs,
2. both fusion proteins are produced in expression systems,
3. both fusion proteins are single chain polypeptides,
4. both fusion proteins have two (or three) domains,
5. both fusion proteins (may) have linkers to separate domains from each other,
6. both fusion proteins have the same functions: bind both T cells and B (or other) cells and
7. both fusion proteins have the same mechanism of action: direct T cells against B (or other) cells.

This information is important for investors, because by using this information, every competitor of Micromet can invalidate (for example via reexaminations within USPTO by third parties) these above mentioned key patents of Micromet and prevent patent issues for these key patent applications of Micromet.
Invalidations may lead to free manufacture and commercialization of these anticancer fusion proteins. Below are the links to the according publications in patent literature:

DE10161738 (Fusion Proteins against T cell tumors)

DE10161899 (Fusion Proteins against Hodgkin’s disease)

DE10162870 (Fusion Proteins against B cell tumors)







2. The invention for treatment of autoimmune diseases such as multiple
sclerosis (said invention are the Fc-autoantigen fusion proteins such
as for example Fc-AchR fusion protein in order to treat
myasthenia gravis) is disclosed in Micromet’s US patent US7323440, issued by error of examiner Mertz (priority date: February 13, 2002 (EP02003332)), especially in
examples 19-24, where the illustrative and inventive fusion protein
Fc-AchR was implemented (Example 19, 19.1-19.3, and 20), but the same
invention of Fc-autoantigen and Fc-AchR fusion proteins was disclosed
in my prior German patent application DE10161248 (priority date:
December 07, 2001).
Below are the links to DE10160248 and US7323440:



3. The German company Evotec NeuroSciences together with the
University of Zurich experimentally proved my invention of fusion
proteins comprising protease and specific binding domain in order to
treat diseases associated with pathogenic proteins, such Alzheimer's
disease. And they did not mention my prior patent application
DE19822406A1 and the article in Stern (The Star, March 25, 1999),
where this my invention was described and named revolution. Stern is
the most popular magazine in Germany and Stern observed my
participation and presentation by "Youth research" (Jugend forscht) in 1999.
My patent application DE19822406 for this invention, especially for
protease fusion proteins specifically for cleaving amyloid proteins in
order to treat amyloid diseases causally, was filed with the German
Patent and Trademark Office on May 19,1998 and was published on
November 25, 1999. The group of Roger Nitsch, Johannes Pohlner, Axel
Wollmer and Hasan Mohajeri which were employed at Evotec NeuroSciences
GmbH in Germany and at the University of Zurich, tried to get patents
for "Methods and compounds for treating brain amyloidosis", which is
the invention of mine. They filed the European patent application
EP00120449.4 on September 19, 2000 and then international patent application
WO0225279, PCT/EP01/10816, as well as two US patent applications
US20040038302 (filed on July 29, 2003 in the US) and US20060142194
(filed on November 16, 2005). Thus I have the inventorship and
priority. These their patent applications do not contain references to
me and my prior published documents.
The following are the according links:




In addition to the fact of my priority and authorship of my invention,
it is well documented that my theoretical inventions have been
confirmed by experiments and that my inventions deserve to be
implemented commercially.

4. Japanese group of Kyohei Terao, Masao Washizu and Hidehiro Oana
experimentally confirmed my inventions for sequencing and manipulation
of giant DNA sequences described in my two German patents DE19929530B4
and DE19937512B4 filed in 1999 and published in 2001. In my German
patent DE19929530B4 is described my invention of ordered winding DNA
around the bobbins and this work was carried out by the
above-mentioned Japanese group and claimed as sensation. Their paper
"On-site manipulation of single chromosomal DNA molecules by using
optically driven microstructures" was published on June 23, 2008 in
the journal Lab on a Chip of the Royal Society of Chemistry in the UK.
Their work was highlighted in Chemical Science and in New Scientist.
Thereby my German patent DE 19937512 was mentioned by American
inventor Rouvain Bension in his US patent US7163658.
Below are links to the patents DE19929530, DE19937512 and US7163658 as
well as to certain related articles:

5. The Nobel Laureate Joshua Lederberg tried to get priority for the
invention for which I have well documented priority. This invention
concerns genetically engineered medicine carriers especially
bacteriophage-antibody and bacteriophage-receptor complexes against
bacterial diseases and cancer. His US patent application 20040033584
was filed as a PCT international application on December 21, 2000, it
means later than my earlier German patent application DE19818938A1,
filed on April 28, 1998 and published in November 4, 1999.
Lederberg was a famous scientist and is considered as the father of
molecular biotechnology and his experiments were basis for the
experiments of Stanley N. Cohen and Herbert Boyer, inventors of
recombinant DNA technology, of genetic engineering.
Below are the links to DE 19818938 and US 20040033584:

So my theoretical inventions presented by myself as student at
gymnasium and university have been confirmed experimentally. These
facts are also confirmations that my inventions work and are worthy to
be implemented commercially.

Dipl.-Biol. (MSc) Alexander Cherkasky